ArticleBlood advances2023
Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis.
Open access · goldAbstract read
In one paragraph
Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 22 citations in OpenAlex.
- Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Review
- First-line tagraxofusp leads to durable responses and prolonged survival in adults with blastic plasmacytoid dendritic cell neoplasm regardless of fitness level.Haematologica · 2026Article
- Isatuximab induces antitumor activity in blastic plasmacytoid dendritic cell neoplasm through cellular cytotoxicity.Leukemia · 2026Article
- BRD4-associated chromatin remodelling signature links epigenetic regulation to immune landscape in ovarian cancer.Journal of ovarian research · 2026Article
- Blastic plasmacytoid dendritic cell neoplasm: A single centre Indian experience.Leukemia research reports · 2026Article
- Tissue-Resident Myeloid and Histiocytic Cells in Health and Disease: Novel Emerging Concepts.American journal of hematology · 2025Review
- Prospective clinical trials of venetoclax and hypomethylating agents for relapsed BPDCN.Blood neoplasia · 2025Article
- Diagnostic approach to blastic plasmacytoid dendritic cell neoplasm: historical perspectives and current understanding.Journal of clinical and experimental hematopathology : JCEH · 2025Review
- Tagraxofusp maintenance post-hematopoietic stem cell transplantation provides long-term survival and manageable safety for a patient with blastic plasmacytoid dendritic cell neoplasm.Leukemia research reports · 2025Article
- BPDCN: state of the art.Hematology. American Society of Hematology. Education Program · 2024Review
- Overcoming Tagraxofusp-Erzs Monotherapy Resistance in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in a Real-World Clinical Setting.Journal of immunotherapy and precision oncology · 2024Article
- Blastic Plasmacytoid Dendritic Cell Neoplasm, from a Dermatological Point of View.International journal of molecular sciences · 2024Review
- Review
- Thiotepa-busulfan-fludarabine-based conditioning as a promising approach prior to allogeneic hematopoietic stem cell transplantation in patients with blastic plasmacytoid dendritic cell neoplasm.Annals of hematology · 2024Article
- Simultaneous blastic plasmacytoid dendritic cell neoplasm and myelofibrosis: A case report.Oncology letters · 2024Article
- A 31-year-old male with a plasmacytoid dendritic blast cell neoplasm.Ecancermedicalscience · 2024Article
- Challenges and practical considerations in the management of blastic plasmacytoid dendritic cell neoplasm: A single-center experience.Leukemia research reports · 2024Article
- Real-world evidence on tagraxofusp for blastic plasmacytoid dendritic cell neoplasm - collected cases from a single center and case reports.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
69 authors at 20 institutions in 9 countries.
Hemant S MurthyDivision of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL.ORCID 0000-0003-4534-4248
Mei-Jie ZhangDivision of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI.
Karen ChenCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
Sairah AhmedDepartment of Lymphoma/Myeloma and Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-7302-8299
Uday DeotareLondon Health Sciences Centre, Toronto, ON, Canada.
Siddhartha GangulyHouston Methodist Hospital and Neal Cancer Center, Houston, TX.
Ankit KansagraBlood and Marrow Transplant Program, UT Southwestern Medical Center, Dallas, TX.ORCID 0000-0001-6901-0782
Fotios V MichelisAllogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada.ORCID 0000-0003-2956-0848
Taiga NishihoriDepartment of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL.ORCID 0000-0002-2621-7924
Mrinal PatnaikMayo Clinic Rochester, Rochester, MN.ORCID 0000-0001-6998-662X
Muhammad Bilal AbidDivisions of Hematology/Oncology & Infectious Diseases, Bone and Marrow Transplant & Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI.
Mahmoud AljurfDepartment of Oncology, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia.
Yasuyuki AraiKyoto University Hospital, Kyoto University, Kyoto, Japan.ORCID 0000-0002-9662-5093
Ulrike BacherDepartment of Hematology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Talha BadarDivision of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL.ORCID 0000-0003-1548-918X
Sherif M BadawyDepartment of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL.
Karen BallenDivision of Hematology/Oncology, University of Virginia Health System, Charlottesville, VA.
Minoo BattiwallaSarah Cannon Blood Cancer Network, Nashville, TN.
Amer BeitinjanehDivision of Transplantation and Cellular Therapy, University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center, Miami, FL.
Nelli BejanyanDepartment of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL.ORCID 0000-0003-0194-7338
Vijaya Raj BhattThe Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE.ORCID 0000-0003-2513-0533
Valerie I BrownDivision of Pediatric Oncology/Hematology, Department of Pediatrics, Penn State Hershey Children's Hospital and College of Medicine, Hershey, PA.
Rodrigo MartinoDivision of Clinical Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Jean-Yves CahnDepartment of Hematology, CHU Grenoble Alpes, Université Grenoble Alpes, Grenoble, France.
Paul CastilloUF Health Shands Children's Hospital, Gainesville, FL.
Jan CernyDivision of Hematology/Oncology, Department of Medicine, University of Massachusetts Medical Center, Worcester, MA.
Saurabh ChhabraCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.ORCID 0000-0001-9117-8696
Edward CopelanDepartment of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC.
Andrew DalyTom Baker Cancer Center, Calgary, AB, Canada.
Bhagirathbhai DholariaVanderbilt University Medical Center, Nashville, TN.ORCID 0000-0003-2371-3655
Miguel Angel Diaz PerezDepartment of Hematology/Oncology, Hospital Infantil Universitario Niño Jesus, Madrid, Spain.ORCID 0000-0001-5286-1329
César O FreytesUniversity of Texas Health Science Center at San Antonio, San Antonio, TX.ORCID 0000-0003-2880-6797
Michael R GrunwaldDepartment of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC.
Shahrukh HashmiDepartment of Internal Medicine, Mayo Clinic, Rochester, MN.ORCID 0000-0002-8914-7927
Gerhard C HildebrandtEliis Fischel Cancer Center, University of Missouri, Columbia, MO.
Omer JamyDivision of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.ORCID 0000-0003-2411-4742
Jacinth JosephMethodist Healthcare Blood and Marrow Transplant Center, Memphis, TN.
Christopher G KanakryCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Nandita KheraDepartment of Hematology/Oncology, Mayo Clinic, Phoenix, AZ.
Maxwell M KremKansas City VA Medical Center, Kansas City, MO.ORCID 0000-0003-3980-480X
Yachiyo KuwatsukaDepartment of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.
Hillard M LazarusUniversity Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH.ORCID 0000-0002-1159-5607
Lazaros J LekakisDivision of Transplantation and Cellular Therapy, University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center, Miami, FL.
Hongtao LiuSection of Hematology/Oncology, University of Chicago Medicine, Chicago, IL.ORCID 0000-0002-3190-7807
Dipenkumar ModiDivision of Oncology, Karmanos Cancer Center/Wayne State University, Detroit, MI.ORCID 0000-0001-6525-8844
Pashna N MunshiStem Cell Transplant and Cellular Immunotherapy Program, MedStar Georgetown University Hospital, Washington, DC.
Alberto MussettiClinical Hematology Department, Catalan Institute of Oncology, Hospitalet, Barcelona, Spain.ORCID 0000-0002-4088-036X
Neil PalmisianoSidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
Sagar S PatelTransplant and Cellular Therapy Program, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT.ORCID 0000-0001-9949-3615
David A RizzieriNovant Health Cancer Institute, Winston Salem, NC.
Sachiko SeoDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan.
Mithun Vinod ShahMayo Clinic Rochester, Rochester, MN.ORCID 0000-0002-5359-336X
Akshay SharmaDepartment of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0003-3281-2081
Melhm SohlThe Blood and Marrow Transplant Group of Georgia, Northside Hospital, Atlanta, GA.
Scott R SolomonBlood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA.
Matthew UlricksonBanner MD Anderson Cancer Center, Gilbert, AZ.
Celalettin UstunDivision of Hematology/Oncology/Cell Therapy, Rush University, Chicago, IL.ORCID 0000-0001-6896-6213
Marjolein van der PoelDivision of Hematology, Department of Internal Medicine, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
Leo F VerdonckDepartment of Hematology/Oncology, Isala Clinic, Zwolle, The Netherlands.
John L WagnerDepartment of Medical Oncology, Thomas Jefferson University, Philadelphia, PA.ORCID 0000-0001-8468-6764
Trent WangDivision of Transplantation and Cellular Therapy, University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center, Miami, FL.
Baldeep WirkBone Marrow Transplant Program, Penn State Cancer Institute, Hershey, PA.
Amer ZeidanBridgeport Hospital, Yale University School of Medicine, New Haven, CT.
Mark LitzowMayo Clinic Rochester, Rochester, MN.ORCID 0000-0002-9816-6302
Partow KebriaeiDivision of Cancer Medicine, Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX.
Christopher S HouriganLaboratory of Myeloid Malignancies, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0002-6189-8067
Daniel J WeisdorfDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN.ORCID 0000-0001-8078-8579
Wael SaberCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
Mohamed A Kharfan-DabajaDivision of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL.ORCID 0000-0001-7394-5185
Medical College of Wisconsin · USMayo Clinic · USMayo Clinic in Florida · USThe University of Texas MD Anderson Cancer Center · USUniversity of Miami Hospital · USLevine Cancer Institute · USNational Institutes of Health · USNorthside Hospital · USThomas Jefferson University · USCentre Hospitalier Universitaire de Grenoble · FRDokkyo Medical University · JPGeorgetown University · USHospital de Sant Pau · ESHospital Infantil Universitario Niño Jesús · ESHouston Methodist · USInstitut d'Investigació Biomédica de Bellvitge · ESIsala · NLKansas City VA Medical Center · USKing Faisal Specialist Hospital & Research Centre · SAKyoto University Hospital · JP
Funding
Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2MYale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MUM Calabresi Clinical Oncology Research Career Development AwardK12CA226330 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Alan Pollack · 2018 to 2026
$5.1MNTP INFORMATION SYSTEMS SUPPORT27305C0011 · NIEHS · Z-TECH CORPORATION · 2007 to 2009
$4.3MPROVIDE RABBITS, RATS, MICE, HAMSTERS, GERBILS, GUINEA PIGS27307C0011 · NIEHS · PI BOLEN, WAYNE · 2007 to 2007
$500kNCATS NIH HHS UL1 TR001863NCI NIH HHS K12 CA226330NCI NIH HHS U24 CA076518NIEHS NIH HHS 27305C0011NIEHS NIH HHS 27307C0011NIEHS NIH HHS 27398C0011
Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with a poor prognosis and considered incurable with conventional chemotherapy. Small observational studies reported allogeneic hematopoietic cell transplantation (allo-HCT) offers durable remissions in patients with BPDCN. We report an analysis of patients with BPDCN who received an allo-HCT, using data reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). We identified 164 patients with BPDCN from 78 centers who underwent allo-HCT between 2007 and 2018. The 5-year overall survival (OS), disease-free survival (DFS), relapse, and nonrelapse mortality (NRM) rates were 51.2% (95% confidence interval [CI], 42.5-59.8), 44.4% (95% CI, 36.2-52.8), 32.2% (95% CI, 24.7-40.3), and 23.3% (95% CI, 16.9-30.4), respectively. Disease relapse was the most common cause of death. On multivariate analyses, age of ≥60 years was predictive for inferior OS (hazard ratio [HR], 2.16; 95% CI, 1.35-3.46; P = .001), and higher NRM (HR, 2.19; 95% CI, 1.13-4.22; P = .02). Remission status at time of allo-HCT (CR2/primary induction failure/relapse vs CR1) was predictive of inferior OS (HR, 1.87; 95% CI, 1.14-3.06; P = .01) and DFS (HR, 1.75; 95% CI, 1.11-2.76; P = .02). Use of myeloablative conditioning with total body irradiation (MAC-TBI) was predictive of improved DFS and reduced relapse risk. Allo-HCT is effective in providing durable remissions and long-term survival in BPDCN. Younger age and allo-HCT in CR1 predicted for improved survival, whereas MAC-TBI predicted for less relapse and improved DFS. Novel strategies incorporating allo-HCT are needed to further improve outcomes.
Indexed as
Hematopoietic Stem Cell TransplantationMyeloproliferative DisordersAcute DiseaseChronic DiseaseDendritic CellsHumansMiddle AgedNeoplasm Recurrence, LocalRecurrenceTransplantation, Homologous
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.